# Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers

> **NCT07672574** · PHASE1 · RECRUITING · sponsor: **Agomab Spain S.L.U.** · enrollment: 8 (estimated)

## Conditions studied

- Fibrostenotic Crohn's Disease

## Interventions

- **DRUG:** Ontunisertib
- **DRUG:** [14C]ontunisertib
- **DRUG:** [14C]ontunisertib

## Key facts

- **NCT ID:** NCT07672574
- **Lead sponsor:** Agomab Spain S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-09
- **Primary completion:** 2026-09-26
- **Final completion:** 2026-09-26
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672574, "Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*